

20 Feb 2020 | Analysis

QUOTED. 20 February 2020. Steven Raman.

by

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

"There are two very unique things about this system. First, you can control with much more finesse where you're going to treat, preserving continence and sexual function. Second, you can do this for both diffuse and localized prostate cancer and benign diseases, including benign hyperplasia." – Steven Raman, professor of radiology and urology, University of California, Los Angeles

- Find out more: [Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market](#)

[Click here](#) for a free trial of *Medtech Insight*